Monday, April 4, 2016

BRIEF-Vericel says phase 2b Ixcell-DCM clinical trial met its primary endpoint

* Results from Vericel's positive phase 2b Ixcell-DCM clinical trial of Ixmyelocel-T presented today at ACC and published in the Lancet











Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)